Impacts of Biosimilars

Impacting the entire healthcare system

We’re committed to the development of biosimilars because of the additional treatment options they provide to patients and the positive impact they can have on the entire healthcare system.¹

At a time when healthcare costs are rising, we aspire to contribute to a more sustainable healthcare system by providing more options through our biosimilar medicines.¹

Amgen's 8th Annual Biosimilar Trends Report

Since the first biosimilar entered the US marketplace in 2015, biosimilars have gained significant share in the majority of therapeutic areas where they have been introduced. With 21 biosimilars available in the US as of September 2021, the US marketplace is poised to see further growth in biosimilars approved to date, and welcome many new biosimilars in the years to come.

Impacting each and every patient

At the heart of Amgen’s commitment to biosimilars is our mission to serve patients. Quality biosimilars are anticipated to offer more treatment options for patients¹—and we believe that we bring high-quality science to this new space in healthcare.

We want to help patients access the medicines they need. With increased availability of lower-cost biosimilars, patients have more options to choose the right medicine at the right time.

Reference: 1. The Center For Biosimilars. Biosimilars market is ripe for cost savings.
www.centerforbiosimilars.com/contributor/chad-pettit/2019/06/biosimilars-market-is-ripe-for-cost-savings. Accessed October 29, 2019.

Next: highly specialized knowledge Next: Therapeutic Area Commitment